- Bristol Myers may be falling prey to an acquisition.
- Speculation of Opdivo drove harsh sell offs.
- All recent hype aside, Bristol Myers is a great biopharma stock for long term growth.
Bristol Myers Squibb (NYSE:BMY) has taken the spotlight recently through news reports of Carl Ichan targeting the company as a takeover opportunity. The stock price has made a 20% rise since January 26th based on news, positive valuation, and being over sold in late 2016. With so much information flooding the internet about Bristol Myers it may be difficult to see through the shroud and come out with a decision to buy, sell, or hold the stock.